Evidence map›Paper›PMID 40135393›Full record

ArticleJournal of veterinary internal medicine

A Retrospective Study of Chemotherapy-Related Extravasation Events in Dogs and Cats.

Elise Martens, Rachel Hritz, Craig Clifford, Christine Mullin, Corrine Camero, Kai-Biu Shiu, Catherine Chan, Chelsea Del Alcazar, Carol DeRegis, Lindsay Donnelly and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Elise MartensDepartment of Clinical Sciences, Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA.
Rachel HritzDepartment of Clinical Sciences, Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA.
Craig CliffordBluePearl Malvern, Malvern, Pennsylvania, USA.
Christine MullinBluePearl Malvern, Malvern, Pennsylvania, USA.
Corrine CameroCare Center, Cincinnati, Ohio, USA.
Kai-Biu ShiuVCA VESVSC Madison, Madison, Wisconsin, USA.ORCID https://orcid.org/0009-0004-0201-2133
Catherine ChanThe Pet Oncologist, Brisbane, Queensland, Australia.
Chelsea Del AlcazarFriendship Hospital for Animals, Washington, District of Columbia, USA.
Carol DeRegisPieper Veterinary, Middletown, Connecticut, USA.
Lindsay DonnellyVeterinary Medicine and Surgery Department, Veterinary Health Center, University of Missouri, Columbia, Missouri, USA.ORCID https://orcid.org/0000-0001-9116-7428
Bryan MarkerSAGE Veterinary Center, Redwood City, California, USA.
Katarzyna PurzyckaAndersonMoores Veterinary Specialists, The Granary, Winchester, UK.
Kathryn VickeryDepartment of Clinical Sciences, Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA.ORCID https://orcid.org/0009-0006-7832-4832

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapy extravasation is a potentially serious complication. There is a paucity of information in the veterinary literature investigating extravasation events, treatments, and outcomes.

objectiveEvaluate chemotherapy extravasation events and treatments in dogs and cats, adverse events (AEs), and overall outcomes. ANIMALS: Twenty dogs and three cats were included.

methodsRetrospective, multicenter, descriptive study including dogs or cats with suspected extravasation from chemotherapy. Information obtained included: signalment, extravasation details and treatment provided, AEs graded according to VCOG-CTCAE v2 criteria, and outcome.

resultsThe most common drug extravasated was doxorubicin, followed by carboplatin. Carboplatin extravasation (n = 5) resulted in Grades III-IV AEs, all of which required surgical debridement. Doxorubicin extravasation (n = 9) resulted in Grades 0-V AEs, two of which amputation was ultimately recommended, and one of those two was euthanized instead. Extravasation of vinca alkaloids (n = 5) and rabacfosadine (n = 1) resulted in Grades II-III AEs, all managed in the outpatient setting. Mitoxantrone (n = 2) and dacarbazine (n = 1) extravasation resulted in no clinical signs associated with extravasation injury. Seventy-eight percent (18/23) cases had extravasation occur during one of the first four treatments of chemotherapy, with 30% (7/23) occurring during the first chemotherapy treatment. CONCLUSIONS AND CLINICAL IMPORTANCE: Most cases (20/23) had mild to moderate or no AEs. Findings support that carboplatin should be considered a vesicant.

Indexed as

Antineoplastic AgentsCat DiseasesDog DiseasesExtravasation of Diagnostic and Therapeutic MaterialsAnimalsCarboplatinCatsDogsFemaleMaleNeoplasmsRetrospective StudiesAntineoplastic AgentsCarboplatinadverse eventscatdogextravasationveterinary

Identifiers

PMID40135393
PMCPMC11937848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.